T. Rowe Price Associates
NUVB icon

T. Rowe Price Associates’s Nuvation Bio NUVB Stock Holding History

T. Rowe Price Associates’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Sell
303,624
-2,404,929
-89% -$13.4M ﹤0.01% 2012
2025
Q4 		$24.3M Buy
2,708,553
+2,424,109
+852% +$15M ﹤0.01% 1016
2025
Q3 		$1.05M Buy
284,444
+7,124
+3% +$19.4K ﹤0.01% 2042
2025
Q2 		$541K Buy
277,320
+45,499
+20% +$94.8K ﹤0.01% 2265
2025
Q1 		$409K Buy
231,821
+6,796
+3% +$15.5K ﹤0.01% 2332
2024
Q4 		$599K Buy
225,025
+9,758
+5% +$25.1K ﹤0.01% 2209
2024
Q3 		$493K Sell
215,267
-5,052
-2% -$15.4K ﹤0.01% 2246
2024
Q2 		$644K Sell
220,319
-1,134,313
-84% -$3.46M ﹤0.01% 2086
2024
Q1 		$4.93M Buy
1,354,632
+1,146,794
+552% +$2.2M ﹤0.01% 1221
2023
Q4 		$314K Sell
207,838
-584,073
-74% -$752K ﹤0.01% 2357
2023
Q3 		$1.06M Sell
791,911
-13,908
-2% -$23.1K ﹤0.01% 1767
2023
Q2 		$1.45M Sell
805,819
-48,848
-6% -$83K ﹤0.01% 1612
2023
Q1 		$1.42M Sell
854,667
-20,170
-2% -$40.9K ﹤0.01% 1612
2022
Q4 		$1.68M Sell
874,837
-36,696
-4% -$74.2K ﹤0.01% 1534
2022
Q3 		$2.04M Buy
911,533
+826,426
+971% +$2.36M ﹤0.01% 1446
2022
Q2 		$276K Buy
85,107
+34,653
+69% +$151K ﹤0.01% 2478
2022
Q1 		$265K Buy
50,454
+13,212
+35% +$74.2K ﹤0.01% 2601
2021
Q4 		$317K Buy
37,242
+23,166
+165% +$213K ﹤0.01% 2578
2021
Q3 		$140K Buy
14,076
+2,593
+23% +$23.5K ﹤0.01% 2783
2021
Q2 		$107K Buy
+11,483
New +$131K ﹤0.01% 2837

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's NUVB Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Nuvation Bio (NUVB) stake by 89% in Q1 2026, selling an estimated $13.4M and leaving 303,624 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

T. Rowe Price Associates first reported a position in NUVB in Q2 2021 and has held it in 20 quarters since. The position peaked at $24.3M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • T. Rowe Price Associates held 303,624 shares of Nuvation Bio worth $1.3M as of Q1 2026.
  • T. Rowe Price Associates sold 2,404,929 Nuvation Bio shares in Q1 2026, an estimated $13.4M.
  • Nuvation Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2012 holding.
  • T. Rowe Price Associates first reported a position in Nuvation Bio in Q2 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Nuvation Bio position peaked at $24.3M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.